Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Clinical trial NCT05119855 · COMPLETED

Trial details

NCT number: NCT05119855
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Papillomavirus Infections Coronavirus Disease (COVID-19)

Start date: 2022-03-28
Primary completion: 2023-12-12
Enrollment: 165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.